Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

From the Guest Editor
Charles B. Nemeroff, M.D., Ph.D.
FOCUS 2010;8:473-473.
text A A A

FOCUS is truly intended to provide continuing medication education for practitioners that will have an impact on their practice by presenting state-of-the-art, evidence-based medicine. This issue of FOCUS is of particular relevance to psychiatrists because it provides an update on treatment-refractory psychiatric disorders including major depression, anxiety disorders, and schizophrenia. Many patients with psychiatric disorders are treated by nonpsychiatrists including family physicians, general practitioners, and obstetricians/gynecologists. This situation is unavoidable because there are simply too few psychiatrists to treat the large numbers of patients who have these major psychiatric illnesses. Therefore, as psychiatrists, we are referred the substantial numbers of patients with mood and anxiety disorders that do not respond to monotherapy with commonly prescribed psychopharmacological agents such as selective serotonin reuptake inhibitors.

In this issue of FOCUS, we provide overviews of the management of treatment-refractory depression, schizophrenia, and major anxiety disorders. In addition, we provide a look into the future by reviewing the emerging field of personalized medicine in psychiatry, which has the goal of reducing treatment failures in patients with these disorders by matching individual patients with the therapies most likely to successfully treat their symptoms, both psychopharmacologically and psychotherapeutically.

As with all issues of FOCUS, we also have the unique opportunity to publish reprints of several of the seminal publications in the field in their entirety and abstracts of others. This will allow practitioners to have at their disposal in a single issue of the journal a summary of management of patients with treatment-refractory disorders. After reading the entire volume, one inexorable conclusion is reached—psychiatric treatment of these disorders remains far from optimal, and considerably more controlled clinical trials, as well as novel approaches, are needed to further advance the field.




CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe

Related Content
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 1.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 4.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 1.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 52.  >
Topic Collections
Psychiatric News
Read more at Psychiatric News >>
APA Guidelines
PubMed Articles